
APLS
Healthcare · Biotechnology · $5.25B market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2026
EPS trend, 90 days to now · +10.0% over 90 days · 30-day revisions 0 up, 2 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 7, 2026 | Before the open | -0.36 | 0.15 | +141.7% |
| Mar 4, 2026 | Time not confirmed | -0.38 | -0.47 | -24.0% |
| Oct 30, 2025 | Before the open | 0.94 | 1.67 | +77.7% |
| Jul 31, 2025 | Before the open | -0.47 | -0.33 | +29.8% |
| May 7, 2025 | Before the open | -0.35 | -0.74 | -111.4% |
| Feb 25, 2025 | Before the open | -0.40 | -0.29 | +27.8% |
| Nov 5, 2024 | Before the open | -0.27 | -0.46 | -70.4% |
| Aug 1, 2024 | Before the open | -0.32 | -0.29 | +9.4% |
| May 7, 2024 | Before the open | -0.41 | -0.54 | -31.7% |
| Feb 27, 2024 | Before the open | -0.69 | -0.73 | -5.8% |
| Nov 1, 2023 | Before the open | -0.99 | -1.17 | -18.2% |
| Jul 31, 2023 | Before the open | -1.34 | -1.02 | +23.9% |
| May 4, 2023 | After the close | -1.46 |
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company…
| -1.56 |
| -6.8% |
| Feb 21, 2023 | After the close | -1.57 | -1.50 | +4.5% |
| Nov 7, 2022 | After the close | -1.43 | -1.75 | -22.4% |
| Aug 8, 2022 | After the close | -1.36 | -1.46 | -7.4% |
| May 4, 2022 | After the close | -1.19 | -1.42 | -19.3% |
| Feb 28, 2022 | After the close | -1.54 | -1.61 | -4.5% |
| Nov 8, 2021 | After the close | -1.57 | -1.52 | +3.2% |
| Aug 9, 2021 | After the close | -1.66 | -2.46 | -48.2% |
| Apr 28, 2021 | After the close | -1.76 | -1.60 | +9.1% |
| Feb 25, 2021 | After the close | -0.75 | 0.93 | +224.0% |
| Nov 2, 2020 | Before the open | -1.56 | -1.83 | -17.3% |
| Jul 30, 2020 | After the close | -1.35 | -1.61 | -19.3% |
| Apr 29, 2020 | After the close | -1.43 | -1.36 | +4.9% |
| Feb 27, 2020 | After the close | -1.14 | -1.77 | -55.3% |
| Nov 5, 2019 | Before the open | -1.04 | -1.09 | -4.8% |
| Jul 31, 2019 | After the close | -0.74 | -0.98 | -32.4% |
| May 7, 2019 | After the close | -0.62 | -0.84 | -35.5% |
| Feb 26, 2019 | After the close | -0.70 | -0.65 | +7.1% |
| Nov 13, 2018 | Before the open | -0.69 | -0.63 | +8.7% |
| Jul 31, 2018 | After the close | -0.42 | -0.61 | -45.2% |
| Apr 30, 2018 | After the close | -0.33 | -0.43 | -30.3% |
| Mar 19, 2018 | After the close | -0.48 | -0.60 | -25.0% |